Antagonizing the IL-1β signaling resulted in marked reduction of plasma high-sensitivity C-reactive protein (hs-CRP) levels among patients with elevated hs-CRP levels and history of myocardial infarction, which eventually led to decreased major adverse cardiac/CV events (MACE and MACE+) (4) hs-CRP is a predictive marker of the severity of atherosclerosis and extent of future cardiovascular events (5, 6). This evidence concerns the gene IL1B and atherosclerosis.